The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...

Home › GLP-1 Hub › Cost and Coverage 2026 By Dr. Frank Yap, MD , One Day Media Network  |  Published and last verified: October 2026  |  Scope: United States, USD  |  Purpose: cost and coverage education, not individual medical or financial advice Quick Answer In October 2026, advertised US self-pay prices for obesity GLP-1 medicines run from $149 per month (Wegovy pill 1.5 mg; Foundayo 0.8 mg and, through December 31, 2026, 2.5 mg) to $449 per month for most Zepbound KwikPen maintenance doses. Commercially insured patients whose plan covers the drug can pay as little as $25 per month with a manufacturer savings card (capped). Eligible Medicare Part D beneficiaries pay $50 per month through the Medicare GLP-1 Bridge until December 31, 2027. Several offers end on December 31, 2026 . Deadline watch: the Wegovy new-patient injection offer, the Zepbound and Foundayo savings cards, and the temporary Foundayo 2.5 mg ($149) and 5.5 m...